Patents by Inventor Eric Breinlinger

Eric Breinlinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LPAR1 Inhibitors
    Publication number: 20260102383
    Abstract: Provided herein are compounds of Formula (I), compounds of Formula (II) and pharmaceutically acceptable salts thereof, useful as LPAR1 inhibitors, and pharmaceutical compositions comprising the same. Also provided are methods of treating or preventing a disease or condition comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a compound of Formula (II).
    Type: Application
    Filed: April 18, 2025
    Publication date: April 16, 2026
    Inventors: Henry Korman, Allan C. Krueger, Eric Breinlinger, Noel S. Wilson, Kyle R. Owens, Howard R. Heyman, James N. Newton, Anurupa Shrestha, Martin Garcia Chavez, Gang Zhao, Bo Liu, Daniel Hamza, Thomas D. Ackrill, Jayde A. McLellan, Alexander J. Leeder
  • Indazolones as modulators of tnf signaling
    Patent number: 10160748
    Abstract: The disclosure provides indazolone compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the disclosure may be useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: December 25, 2018
    Assignee: AbbVie Inc.
    Inventors: Maria Argiriadi, Eric Breinlinger, Justin D. Dietrich, Michael Friedman, David Ihle, Michael Morytko, Kelly Mullen, Augustine Osuma, Gloria Y. LoSchiavo, Noel S. Wilson
  • INDAZOLONES AS MODULATORS OF TNF SIGNALING
    Publication number: 20180086737
    Abstract: The disclosure provides indazolone compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the disclosure may be useful for treating immunological and oncological conditions.
    Type: Application
    Filed: August 7, 2017
    Publication date: March 29, 2018
    Inventors: Maria Argiriadi, Eric Breinlinger, Justin D. Dietrich, Michael Friedman, David Ihle, Michael Morytko, Kelly Mullen, Augustine Osuma, Gloria Y. LoSchiavo, Noel S. Wilson
  • Indazolones as modulators of TNF signaling
    Patent number: 9879016
    Abstract: The disclosure provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: January 30, 2018
    Assignee: AbbVie Inc.
    Inventors: Eric Breinlinger, Andrew Burchat, Justin Dietrich, Michael Friedman, David Ihle, David Kinsman, Kelly Mullen, Augustine Osuma, Anil Vasudevan, Noel Wilson
  • INDAZOLONES AS MODULATORS OF TNF SIGNALING
    Publication number: 20160304496
    Abstract: The disclosure provides indazolone compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the disclosure may be useful for treating immunological and oncological conditions.
    Type: Application
    Filed: April 15, 2016
    Publication date: October 20, 2016
    Inventors: Maria Argiriadi, Eric Breinlinger, Justin D. Dietrich, Michael Friedman, David Ihle, Michael Morytko, Kelly Mullen, Augustine Osuma, Glora Y. Lo Schiavo, Noel S. Wilson
  • INDAZOLONES AS MODULATORS OF TNF SIGNALING
    Publication number: 20160304526
    Abstract: The disclosure provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: April 15, 2016
    Publication date: October 20, 2016
    Inventors: Eric Breinlinger, Andrew Burchat, Justin Dietrich, Michael Friedman, David Ihle, David Kinsman, Kelly Mullen, Augustine Osuma, Anil Vasudevan, Noel Wilson
  • 6H-IMIDAZO[1,5-a]PYRROLO[2,3-e]PYRAZINE COMPOUNDS
    Publication number: 20140315883
    Abstract: The invention provides a compound of Formula (I as defined herein, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: April 18, 2014
    Publication date: October 23, 2014
    Applicant: ABBVIE INC.
    Inventors: Eric Breinlinger, Heather Davis, Michael Hoemann, Bin Li, Biqin Li, Gagandeep Somal, Stacy Van Epps, Lu Wang, Lu Wang
  • 2-Imino-benzimidazoles
    Publication number: 20070232673
    Abstract: Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.
    Type: Application
    Filed: January 19, 2007
    Publication date: October 4, 2007
    Inventors: Gregory Roth, Grier Wallace, Dawn George, Pintipa Grongsaard, Martin Hayes, Eric Breinlinger